Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
<i>Background</i>: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in <i>EGFR</i> mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exp...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/10/2685 |
| _version_ | 1797514987027038208 |
|---|---|
| author | Lorenzo Belluomini Silvia Teresa Riva Michele Simbolo Riccardo Nocini Ilaria Trestini Alice Avancini Daniela Tregnago Miriam Grazia Ferrara Alberto Caldart Alessandra Dodi Anna Caliò Emilio Bria Aldo Scarpa Michele Milella Jessica Menis Sara Pilotto |
| author_facet | Lorenzo Belluomini Silvia Teresa Riva Michele Simbolo Riccardo Nocini Ilaria Trestini Alice Avancini Daniela Tregnago Miriam Grazia Ferrara Alberto Caldart Alessandra Dodi Anna Caliò Emilio Bria Aldo Scarpa Michele Milella Jessica Menis Sara Pilotto |
| author_sort | Lorenzo Belluomini |
| collection | DOAJ |
| description | <i>Background</i>: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in <i>EGFR</i> mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exploring the impact of <i>EGFR</i> targeting in both neoadjuvant and adjuvant settings, underlying <i>lights and shadows</i> and discussing the existing open issues. <i>Methods</i>: We performed a comprehensive search using PubMed and the proceedings of major international meetings to identify neoadjuvant/adjuvant trials with <i>EGFR</i> tyrosine kinase inhibitors (TKIs) in NSCLC. <i>Results</i>: Limited data are available so far about the activity/efficacy of neoadjuvant TKIs in <i>EGFR</i> mutant NSCLC, with only modest downstaging and pathological complete response rates reported. Differently, the ADAURA trial already proposed osimertinib as a potential new standard of care in resected NSCLC harboring an activating <i>EGFR</i> mutation. <i>Conclusion</i>: Anticipating targeted therapy to early stage <i>EGFR</i> mutant NSCLC presents great opportunities but also meaningful challenges in the current therapeutic/diagnostic pathway of lung cancer care. Appropriate endpoint(s) selection for clinical trials, disease progression management, patients’ and treatment selection, as well as need to address the feasibility of molecular profiling anticipation, represent crucial issues to face before innovation can move to early stages. |
| first_indexed | 2024-03-10T06:39:18Z |
| format | Article |
| id | doaj.art-31a48330cf6b4b1e9c3eaed6e2e77fac |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T06:39:18Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-31a48330cf6b4b1e9c3eaed6e2e77fac2023-11-22T17:47:31ZengMDPI AGCells2073-44092021-10-011010268510.3390/cells10102685Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone UnturnedLorenzo Belluomini0Silvia Teresa Riva1Michele Simbolo2Riccardo Nocini3Ilaria Trestini4Alice Avancini5Daniela Tregnago6Miriam Grazia Ferrara7Alberto Caldart8Alessandra Dodi9Anna Caliò10Emilio Bria11Aldo Scarpa12Michele Milella13Jessica Menis14Sara Pilotto15Section of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, ItalyOtolaryngology—Head and Neck Surgery Department, University of Verona Hospital Trust, 37126 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00100 Rome, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, ItalyComprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00100 Rome, ItalySection of Pathology, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, ItalySection of Oncology, Department of Medicine, University of Verona Hospital Trust, 37134 Verona, Italy<i>Background</i>: The current treatment landscape of early stage lung cancer is rapidly evolving, particularly in <i>EGFR</i> mutant non-small cell lung cancer (NSCLC), where target therapy is moving to early stages. In the current review, we collected the available data exploring the impact of <i>EGFR</i> targeting in both neoadjuvant and adjuvant settings, underlying <i>lights and shadows</i> and discussing the existing open issues. <i>Methods</i>: We performed a comprehensive search using PubMed and the proceedings of major international meetings to identify neoadjuvant/adjuvant trials with <i>EGFR</i> tyrosine kinase inhibitors (TKIs) in NSCLC. <i>Results</i>: Limited data are available so far about the activity/efficacy of neoadjuvant TKIs in <i>EGFR</i> mutant NSCLC, with only modest downstaging and pathological complete response rates reported. Differently, the ADAURA trial already proposed osimertinib as a potential new standard of care in resected NSCLC harboring an activating <i>EGFR</i> mutation. <i>Conclusion</i>: Anticipating targeted therapy to early stage <i>EGFR</i> mutant NSCLC presents great opportunities but also meaningful challenges in the current therapeutic/diagnostic pathway of lung cancer care. Appropriate endpoint(s) selection for clinical trials, disease progression management, patients’ and treatment selection, as well as need to address the feasibility of molecular profiling anticipation, represent crucial issues to face before innovation can move to early stages.https://www.mdpi.com/2073-4409/10/10/2685NSCLCEGFRearly stageearly profilingADAURA |
| spellingShingle | Lorenzo Belluomini Silvia Teresa Riva Michele Simbolo Riccardo Nocini Ilaria Trestini Alice Avancini Daniela Tregnago Miriam Grazia Ferrara Alberto Caldart Alessandra Dodi Anna Caliò Emilio Bria Aldo Scarpa Michele Milella Jessica Menis Sara Pilotto Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned Cells NSCLC EGFR early stage early profiling ADAURA |
| title | Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned |
| title_full | Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned |
| title_fullStr | Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned |
| title_full_unstemmed | Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned |
| title_short | Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned |
| title_sort | anticipating egfr targeting in early stages of lung cancer leave no stone unturned |
| topic | NSCLC EGFR early stage early profiling ADAURA |
| url | https://www.mdpi.com/2073-4409/10/10/2685 |
| work_keys_str_mv | AT lorenzobelluomini anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT silviateresariva anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT michelesimbolo anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT riccardonocini anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT ilariatrestini anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT aliceavancini anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT danielatregnago anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT miriamgraziaferrara anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT albertocaldart anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT alessandradodi anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT annacalio anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT emiliobria anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT aldoscarpa anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT michelemilella anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT jessicamenis anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned AT sarapilotto anticipatingegfrtargetinginearlystagesoflungcancerleavenostoneunturned |